Functional variation in allelic methylomes underscores a strong genetic contribution and reveals novel epigenetic alterations in the human epigenome by Cheung, WA et al.
RESEARCH Open Access
Functional variation in allelic methylomes
underscores a strong genetic contribution
and reveals novel epigenetic alterations in
the human epigenome
Warren A. Cheung1,2†, Xiaojian Shao1,2†, Andréanne Morin1,2†, Valérie Siroux3, Tony Kwan1,2, Bing Ge1,2, Dylan Aïssi3,
Lu Chen4,5, Louella Vasquez4, Fiona Allum1,2, Frédéric Guénard6, Emmanuelle Bouzigon7, Marie-Michelle Simon2,
Elodie Boulier2, Adriana Redensek2, Stephen Watt4, Avik Datta8, Laura Clarke8, Paul Flicek8, Daniel Mead4,
Dirk S. Paul9,10, Stephan Beck9, Guillaume Bourque1,2, Mark Lathrop1,2, André Tchernof11, Marie-Claude Vohl6,
Florence Demenais7, Isabelle Pin3,12, Kate Downes5,13, Hendrick G. Stunnenberg14, Nicole Soranzo4,5,15,16,
Tomi Pastinen1,2* and Elin Grundberg1,2*
Abstract
Background: The functional impact of genetic variation has been extensively surveyed, revealing that genetic
changes correlated to phenotypes lie mostly in non-coding genomic regions. Studies have linked allele-specific
genetic changes to gene expression, DNA methylation, and histone marks but these investigations have only been
carried out in a limited set of samples.
Results: We describe a large-scale coordinated study of allelic and non-allelic effects on DNA methylation, histone
mark deposition, and gene expression, detecting the interrelations between epigenetic and functional features at
unprecedented resolution. We use information from whole genome and targeted bisulfite sequencing from 910
samples to perform genotype-dependent analyses of allele-specific methylation (ASM) and non-allelic methylation
(mQTL). In addition, we introduce a novel genotype-independent test to detect methylation imbalance between
chromosomes. Of the ~2.2 million CpGs tested for ASM, mQTL, and genotype-independent effects, we identify ~32%
as being genetically regulated (ASM or mQTL) and ~14% as being putatively epigenetically regulated. We also show
that epigenetically driven effects are strongly enriched in repressed regions and near transcription start sites, whereas
the genetically regulated CpGs are enriched in enhancers. Known imprinted regions are enriched among epigenetically
regulated loci, but we also observe several novel genomic regions (e.g., HOX genes) as being epigenetically regulated.
Finally, we use our ASM datasets for functional interpretation of disease-associated loci and show the advantage of
utilizing naïve T cells for understanding autoimmune diseases.
Conclusions: Our rich catalogue of haploid methylomes across multiple tissues will allow validation of epigenome
association studies and exploration of new biological models for allelic exclusion in the human genome.
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Background
The classic first step of the central dogma of molecular
biology, whereby information flows from the genome to
the transcriptome before continuing to the proteome
and the final phenotypic result, is nowadays bolstered
and modified by an ever-increasing pool of epigenetic
effects. Recent next-generation sequencing (NGS) ap-
proaches provide us with the opportunity to interrogate
not only the genome and the transcriptome but also epi-
genetic layers using comparable technologies. Moreover,
the use of single-base resolution sequencing allows us to
distinguish individual-level genetic differences, giving us
the additional ability to resolve differences between indi-
vidual chromosomes, allowing an allelically resolved
view of epigenetic modifications and gene expression
linked through personal genetics.
Understanding the functional non-coding variation
underlining complex disease has been one of the key
challenges in the past years. Genome-wide association
studies (GWAS) revealed that the majority of the
associated single nucleotide polymorphisms (SNPs) lie in
non-coding regulatory regions [1, 2]. To understand the
functional impact of these SNPs, various studies have
linked these to cellular traits, including gene expression
(expression quantitative trait loci (eQTLs) or allele-
specific expression (ASE) and splicing QTLs) [3–6], DNA
methylation (mQTLs) [7, 8], histone marks (hQTLs), or
allele specific chromatin immunoprecipitation (AS-ChIP))
[9, 10] effects, especially when cell types relevant to the
disease of interest are used. Many of these studies have
confirmed early efforts [1] showing that in fact a majority
of GWAS hits are enriched for these different QTLs.
Allele specific methylation (ASM), where one allele
exhibits a different methylation pattern compared to the
other, has been observed in imprinted genes as well as
in the female sex chromosomes through X-inactivation.
More recently, ASM was found to be prevalent across
the genome [11–13] with the majority of events being
cis-regulated [14]. Also, ASM appears to have a role in
the regulation of the ASE of autosomal non-imprinted
genes. A large portion of ASE events are enriched within
the vicinity of ASM events, where the hypomethylated
allele matches the highly expressed allele [15, 16]. Allele-
specific histone (ASH) has also been linked to allelically
biased gene expression. Allele-specific enhancers are
found close to genes showing ASE, with high concord-
ance of ASH signal to the corresponding ASE of the
same allele [9, 17]. Allele-specific independent events
(methylation, gene expression and histone) have been
shown to have genome-wide, autosomal associations for
complex traits, and particularly for complex disease
[18, 19]. To date, however, the parallel investigation
of ASM, ASH and ASE has only been carried out in
a limited set of samples.
To address this, we have performed the first compre-
hensive survey of the relationship between multiple
epigenetic layers and the functional transcriptome,
evaluating 1446 NGS (RNA-Seq, ChIP-Seq, whole gen-
ome bisulfite sequencing (WGBS), targeted bisulfite se-
quencing (methylC-capture sequencing; MCC-Seq)) data
sets from 910 samples (freshly isolated primary cells or
cryopreserved tissues) for allelic and non-allelic effects
of global DNA methylation. We linked ASM, ASE, and
ASH effects, and directly compared these to non-allelic
effects, which allowed us to establish allelic coordination
of the layers of epigenetics with the transcribed
phenotype.
Results
Allelic and non-allelic patterns of the global DNA
methylation landscape
In order to characterize allelic and non-allelic effects of
DNA methylation at CpGs genome-wide, we utilized
phased NGS data generated from 910 samples derived
from whole blood, adipose tissue, muscle, and purified
monocytes and T cells (Fig. 1a). Specifically, we used our
recently introduced MCC-Seq approach to enrich for
non-coding regulatory sequences [20, 21], thus permit-
ting high-resolution assessment of functional methy-
lomes (Table 1; Additional file 1).
We distinguish between genotype-dependent tests—allele-
specific methylation (ASM) and non-allelic methylation
quantitative trait locus (mQTL) analysis—and a novel
genotype-independent test (GIT) for the identification of
genetically and epigenetically regulated DNA methylation
loci. In our ASM pipeline, phased methylation mea-
surements at single CpG resolution are used together
with a global test to compare the methylation sequen-
cing reads for one allele against those for the other
allele. This allows us to leverage the power of all the
methylation reads across samples at the allelic level to
test for differences in methylation rate of the reads
between the two alleles. For the mQTL analysis, we as-
sess the cis-association (250-kb window surrounding
the CpG) between SNP genotypes and bi-allelic methy-
lation levels across individuals as previously described
[7, 8]. Finally, we use GIT to detect methylation imbal-
ance between chromosomes using phased methylation
measurements. This approach separates the allelic
methylation for each sample into reads for the high
methylated allele and the low methylated allele, then
considers all the reads for the high methylated alleles
together against all reads for the low methylated alleles.
GIT allows us to detect differences in methylation be-
tween the two alleles regardless of the genetics of the
underlying chromosome, permitting us for the first
time to interrogate phased methylation for putative epi-
genetically driven effects.
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We focused on the ~2.2 M CpGs that were tested
using ASM and mQTL analysis and GIT in any of our
datasets and identified a total of 1,043,828 CpGs that
were genetically or epigenetically regulated (Fig. 2). Of
these, 69.7% showed either significant (q < 0.1) ASM
(2.2%) or mQTL (60.1%) or both (7.5%), while the re-
mainder (30.3%) showed potentially significant (q < 0.01)
allelic imbalanced methylation (GIT) without genetic
basis, i.e., that was epigenetically driven (Fig. 2a;
Additional file 2). We noted 543,863 of the regulated
CpGs were significant in the GIT, which identified prox-
imal and distal genetic effects (ASM and mQTL) in
addition to putative epigenetic effects. In addition, 29%
of CpGs significant in the mQTL analysis were also sig-
nificant in the GIT, with 38% of GIT-significant CpGs
also being significant mQTLs. However, despite this sub-
stantial overlap, over half of the mQTLs do not have a
detectable allelic component. In contrast, 74% of the sig-
nificant ASM CpGs were also significant mQTLs. When
restricting to CpGs and SNPs tested by both mQTL and
ASM analyses, we note that the proportion of significant
allelic CpG–SNP pairs replicated in the mQTL analysis
remains comparable at 65%, but the significant GIT
pairs replicated in the ASM analysis is reduced to 17.8%
(Table 2); 31% of the GIT CpGs have a significant
genetic effect that is not from the SNP used for phasing,
potentially indicating more distal regulatory genetic
effects of DNA methylation.
Of the top 500 CpGs (by corrected GIT q value)
deemed to be epigenetically controlled (ASM and mQTL
q ≥ 0.1), 291 (58.2%) CpGs formed clusters of three or
more CpGs within 2 kb. In total, these formed 48 clus-
ters across the genome—23 (47.9%) occurring at known
or presumed imprinted loci, six (12.5%) in the PCDH
gene cluster (reported to be subject to random monoallelic
regulation [22, 23]), and five (13.5%) at potentially novel
imprinted/random monoallelic loci (CTDP1, DIAPH3,
GLS2, ITGB1, and ZNF714). CpG clusters near known
imprinted loci were 124-fold enriched compared to ran-
dom expectation (GREAT analysis [24], p = 1.79 × 10−20).
Fig. 1 Samples having multiple layer of epigenetics profiles were used in this project. DNA methylation profiles were assessed for all samples
using either whole genome bisulfite sequencing (WGBS; green) or targeted bisulfite sequencing (MCC-Seq; red). Listed in this figure are the number of
samples used for analyses focusing on: a methylation sequencing alone (Methyl-Seq), b methylation with matched RNA-Seq from the same
sample, or c methylation sequencing with matched ChIP-Seq (using six different histone marks) and matched RNA-Seq from the same sample
Table 1 Summary of targeted bisulfite-sequencing methylome capture panel design
Total CpGs Total regions Total size (bp)
Regulatory regions in immune cells (DNaseI hypersensitive/active chromatin) 1,837,099 315,043 48,810,975
Hypomethylated footprints from immune cells (MethylSeekR) 3,539,071 477,795 86,414,084
Illumina 450 K methylation assay included regions 1,934,175 328,405 40,853,151
Autoimmune SNPs from GWAS catalog 14,572 7273 678,026
Unique (non-overlapping content) in custom MCC-Seq capture panel 4,609,564 822,884 119,089,296
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This demonstrates that sites identified by GIT specifically
covered a large fraction of genetic-independent allelic
methylation in the human genome. We further generated
a list of high-confidence non-genetic CpG clusters by
examining windows of at least 15 consecutive CpGs and
selecting windows where all CpGs did not show sig-
nificant genetic methylation (ASM and mQTL q ≥ 0.1) but
showed significant imbalanced allelic methylation
(GIT q < 1 × 10−5), and where the median imbalanced al-
lelic methylation was highly significant (loge(q) < −10)
(Additional file 3). As expected, these regions were
enriched for maternal and genetic imprinting (p = 1.65 ×
10−6 and p = 2.79 × 10−5 at 5.4- and 3.6-fold enrichment in
mouse phenotype terms) as well as developmental process
terms (17 of the 20 significant Gene Ontology (GO) bio-
logical process terms). In addition, the developmental pro-
cesses appear to be driven by developmental regulatory
transcription factors (transcription regulatory region
sequence-specific DNA binding p = 3.65 × 10−8, GO mo-
lecular process) with specific 5′ enrichment of imbalanced
methylation (enrichment of HOXL, NKL, and Cadherin
gene families via Interpro and HGNC gene family GREAT
analysis; Additional file 4).
Next, we explored epigenetic and genetic allelic methy-
lation variation in different genomic contexts, via overall
population methylation variation in T cells. Focusing on T
cells allows us to limit the effect of tissue heterogeneity on
overall methylation variation. We inferred genomic con-
texts using states generated from available histone mark
data using ChromHMM [25] (see “Methods”). Direct
(ASM) and indirect effects (mQTLs) account for a large
fraction of total methylation variation; with 28% of the top
57% most variable sites (methylation variance >10) ex-
plained by one of the allelic methylation variation classes
(Fig. 2b). In fact, at highest total methylation variance
(methylation variance >500), essentially all methylation
variation (98%) shows an allelic basis via significant ASM.
In the case of variable methylation in promoter states, the
mQTL approach models a large proportion of the variabil-
ity, which is expected given their overall hypomethylated
status and hence lower potential for detection of signifi-
cant methylation differences between alleles. On the other
hand, genetic ASM is greatly enriched among extremely
variable CpGs, which is likely due to direct strong local in-
fluence of sequence differences altering methylation effi-
ciency [26]. Non-genetic allelic variation accounts for 21%
of highly variable CpGs (methylation variance >10) with a
tendency to explain a higher fraction in repressed states,
suggesting that overall methylation level variation within
these chromatin states arises stochastically in one or the
other allele. These analyses reveal the dichotomous nature
of methylation variation with the relative enrichment of
sequence-dependent variation in canonical regulatory ele-
ments (Fig. 2c, d), and non-genetic variation enriched in
larger repressed or transcriptional annotations.
Cell-type specific DNA methylation events
We also identified cell-type specific CpG methylation
events by comparing genetic and epigenetic CpG methy-
lation that is significant in one or more of our three cell-
types—adipose tissue, naïve T cells, and whole blood
(Table 3, Fig. 3). We compared the CpGs that were
tested in all three cell types and identified the CpGs that
are uniquely significant in the cell type (tissue-specific),
significant in all the cell types, and significant in two of
the cell types. As expected, we see the largest number of
tissue-specific sites in whole blood, which is our tissue
set with the largest number of samples and therefore our
most deeply interrogated tissue type. For mQTLs, we
observe over half of the CpGs are tissue-specific, with
naïve T cells sharing over twice as many CpGs with
whole blood compared to adipose (Fig. 3a). For allele-
specific genetic effects, we see a slightly weaker tissue-
specific effect, especially in adipose tissue. However, over
a quarter of the ASM CpGs are still clearly identified as
tissue-specific (Fig. 3b). The putative epigenetic CpGs
(See figure on previous page.)
Fig. 2 a CpGs showing significant (q < 0.01) imbalanced methylation, significant (q < 0.1) allelic methylation, and significant (q < 0.1) non-allelic
methylation. Percentages indicate the proportion of the total significant CpGs found in any of these three sets (n = 962,557 of the 2,233,846 CpGs
tested in all three tests). b Counts of CpGs showing allele-specific (AS)-genetic (ASM q < 0.1), non-allele-specific (NAS)-genetic (ASM q ≥ 0.1 and
mQTL < 0.1), epigenetic (GIT q < 0.01, ASM and mQTL ≥ 0.1), and no (GIT q > 0.01, ASM and mQTL q ≥ 0.1) associations. Frequencies are plotted for
all the CpGs, and also for CpGs in each of the ChromHMM regions. TSS transcription start site. c Fold change of the rate of putatively
epigenetic (GIT q < 0.01, ASM and mQTL q ≥ 0.1) versus genetic (ASM or mQTL q < 0.1). ***Ratios with Fisher p < 0.0001; all other p values
were >0.05. d Distribution of allelic ratios at significant GIT and ASM CpGs, for H3K27ac and H3K4me1 in normal T cells
Table 2 Summary of CpG phasing SNP overlaps between ASM, GIT, and mQTL
Test A Significant (test A) Test B Significant (test B) Significant (test A and B) Total (test A and B)
ASM 108,515 mQTL 164,671 70,700 2,319,084
GIT 818,954 ASM 158,444 146,012 4,462,724
GIT 603,033 mQTL 164,671 102,663 2,319,084
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show slightly more reduction but we still see almost an
eighth of the identified CpGs acting in a tissue-specific
manner. Moreover, over 50,000 of the putative epigen-
etic CpGs were replicated in all three cell types, replicat-
ing the genotype-independent methylation difference
between alleles in multiple cell type contexts (Fig. 3c).
Next, we took advantage of our rich ASM effects
detected in multiple tissues (i.e., naïve T cells, whole
blood, and visceral adipose tissue) to assess the overlap
between disease-associated loci from eight different
traits: celiac disease [27], Crohn’s disease (CD) [28],
inflammatory bowel disease (IBD) [28], ulcerative colitis
(UC) [28], multiple sclerosis (MS) [29], rheumatoid arth-
ritis (RA) [30], type 1 diabetes (T1D) [31], and type 2
diabetes (T2D) [32] (Fig. 3d). We tested for enrichment
of marginally associated disease SNPs (p < 10-5) for sig-
nificant ASM (q < 0.1) adjusting for linkage disequilib-
rium (LD) structure (r2 < 0.1). We observed strong
enrichment (three- to sevenfold) of autoimmune associa-
tions for ASM in naïve T cells whereas only moderate
enrichment was observed for ASM in whole blood and
even weaker enrichment for adipose ASM. However,
there was a suggestive enrichment (1.6-fold) of T2D loci
for ASM in adipose tissue, which all together suggest
evidence for cell type specificity in functional interpret-
ation of disease loci.
Allelic and non-allelic patterns of non-CpG methylation
Recent studies have shown evidence of non-CpG (or CpH)
methylation in multiple human tissues [15]. However, we
recently showed that CpH methylation might partly be
driven by potentially “erroneous/nonspecific” methylation
from the methylation machinery at neighboring CpGs
[33]. To study this further as well as to characterize allelic
and non-allelic effects of CpH methylation events at the
genome-wide level we extended our analysis to include
CpH sites. We restricted this to sites interrogated in at
least 50 individuals from our deepest covered dataset,
adipose tissue. First, we confirmed our earlier results that
most CpH contexts show complete unmethylation in
adipose tissue [33]; therefore, we restricted the data set to
CpH sites where at least 25 individuals have methylation
greater than zero (N = 189,891 CpHs). Next, we filtered
this set further to exclude CpHs overlapping a SNP
(dbSNP146) at the dinucleotide position (e.g., to avoid an
adjacent SNP creating a CpG context) and then repeated
our ASM and GIT analyses on these CpHs (N = 49,172)
using the same strategy as applied to CpGs. We found that
1627 (3.3%) were significantly associated with an ASM
event (q < 0.1), with a slightly smaller proportion (2.96%)
showing potentially significant allelic imbalanced methyla-
tion (GIT, q < 0.01) without genetic basis. These epigeneti-
cally driven effects on CpH methylation are significantly
smaller (sixfold) than for CpG (Table 3) methylation and
may indicate less dynamic influences on CpH methylation
variation due to an overall static CpH pattern in differenti-
ated cells. Overall, true allelic methylation in a CpH
context remains an extremely rare event, as observed in
non-allelic CpH methylation variation studies [33].
Validation of NGS-based genotype-dependent tests
In an attempt to validate our NGS-based genotype-
dependent tests (i.e., ASM and mQTL), we performed a
number of analyses by comparing results from one of
the cohorts (naïve T cells) with estimates by an inde-
pendent non-NGS based approach—Illumina Infinium
HumanMethylation450 BeadChip (Illumina 450 k array).
To rule out underlying allelic biases in NGS approaches,
we validated our ASM results by comparing our aligned
sequencing results against matched methylation from
the Illumina 450 K array for the same samples (Fig. 1b)
[34]. First, we fetched all CpGs tested in the ASM pipe-
line that were also covered on the 450 K array and con-
firmed the usual pattern of predominantly hypo- and
hypermethylation (Additional file 5: Figure S1a), as well
as a strong correlation (R = 0.97) between the expected
methylation rates (unweighted average of the allelic methy-
lation) called from these sites by MCC-Seq and the rates
estimated by the Illumina 450 k array (Additional file 5:
Figure S1b). Second, by restricting to CpGs showing sig-
nificant ASM (q < 0.1), we noticed a marked shift from the
usual, expected hypo- and hypermethylation towards
hemi-methylation (Additional file 5: Figure S1a) using the
Illumina 450 K array. However, the expected (combined)
methylation called from allelic sequencing at these sites re-
mains highly correlated to the methylation measured via
the array (Additional file 5: Figure S1c; R = 0.92). Taken to-
gether, these results indicate the high accuracy of our
Table 3 Tissue-specific number of CpGs tested and number of significant CpGs for the mQTL, ASM, and GIT analyses
Cell type Naïve T cells Visceral adipose tissue Whole blood Common
All mQTLs tested 3,140,791 1,959,622 4,261,030 1,602,686
Significant mQTLs (q < 0.1) 501,606 170,155 769,853 555,423
All ASM tested 3,109,121 1,713,482 1,636,884 1,079,807
Significant ASM (q < 0.1) 60,559 38,827 81,126 7,682
All GIT tested 2,944,290 1,714,250 1,076,251 622,721
Significant GIT (q < 0.01) 278,516 301,517 486,201 88,599
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detected ASM events with no clear evidence of the pres-
ence of technical artifacts in calling allelic data using NGS
approaches. Next, we focused on our mQTLs identified by
MCC-Seq significant at q < 0.01 and q < 0.001 (Additional
file 5: Figure S1) and fetched overlapping SNPs and
CpG information from the Illumina 450 K array for
the same samples [34]. Here, we note that as much
as 53.8% (for q < 0.01) and 72.0% (for q < 0.001) of the
CpGs lead SNP mQTLs from the MCC-Seq replicate in
the Illumina 450 K data for the same SNP–CpG com-
bination (q < 0.1), confirming the robustness of mQTL
discovery by MCC-Seq.
Allelic analysis to link methylation and gene expression
Next, we contrasted correlations between methylation
and gene expression between the methylome and the
transcriptome in both allele-specific (AS) and non-allele-
specific (NAS) contexts as a proxy for functional out-
comes of methylome variation.
We limited the analysis to individuals where both gene
expression and DNA methylation were available, corre-
sponding to 41 paired RNA-Seq and WGBS samples,
and 122 paired RNA-Seq and MCC-Seq samples (Fig. 1c;
“Methods”; Additional files 1 and 6). In NAS tests, we
correlated total gene expression against total methyla-
tion and compared to AS tests, where allelic methylation
was correlated against allelic gene expression estimates.
Due to the larger number of samples and coverage avail-
able via MCC-Seq, we were able to test a larger number
of CpGs and thus perform more CpG–gene expression
tests, which allowed us to identify more weakly corre-
lated relationships between methylation and gene ex-
pression compared to WGBS.
While the total number of nominally significant (p < 0.05)
correlations detected was slightly lower in AS analyses
(27,324 versus 38,585 in MCC-Seq, 2927 versus 3274 in
WGBS), AS analyses detected a higher rate of strong cor-
relations when compared with NAS correlations for both
MCC-Seq (Fig. 4a) and WGBS (Fig. 4b) across our data-
sets (Kolmogorov–Smirnov p value < 2.2 × 10−16 for both
WGBS and MCC-Seq). We observed significant differ-
ences in the magnitude of the detected correlations from
AS analysis compared to NAS analysis, where the median
NAS significant correlation was R = 0.23 and R = 0.54
for WGBS and MCC-Seq, respectively, compared to the
median AS significant correlations of R = 0.58 and R =
0.83, respectively (chi-squared p value <2.2 × 10−16 at |R|
= 0.5 in both cases). At all quantiles, the AS curve domi-
nates the NAS curve, showing higher correlation values
(Fig. 4c, d). We also assessed the overall concordance be-
tween AS and NAS methylation–expression correlations
(Fig. 4e, f ) and observed, across approaches, that both
analyses have the same direction of effect for significant
associations (R = 0.25, p = 0.0005 and R = 0.47, p < 2. 2 ×
10−16 for WGBS and MCC-Seq, respectively). These ef-
fects were again pronounced in MCC-Seq comparisons,
reflecting the larger number of relationships evaluated
and the wider range of significant correlation values that
could be compared.
Allelic effects on genomic features
We then sought to study the patterns of coordinated
methylation, looking for enrichment of ASM regions in
the context of genomic states. We observed that ASM re-
gions (three or more ASM CpGs) occurred with higher
frequency than expected in enhancer states (WGBS 2.39-
fold, MCC-Seq 1.26-fold; Fisher p < 2. 2 × 10−16) when
compared with all CpGs (Fig. 5a). States associated with
transcription were depleted for ASM regions (WGBS
4.34-fold, MCC-Seq 2.63-fold; p < 2. 2 × 10−16) compared
with all CpGs. These findings support the use of targeted
interrogation of methylomes by MCC-Seq as it success-
fully diverts sequencing from functionally less active re-
gions to regions with functional epigenetic activity. In fact,
by contrasting the two methods (WGBS versus MCC-Seq)
for methylome profiling, we noted that many of the evalu-
ated CpG–gene expression relationships are skewed to-
wards the silent state when using the WGBS method
(40%), whereas MCC-Seq reduces this fraction to 15%
(Fig. 5b). On the other hand, MCC-Seq interrogates
more correlations at enhancer states—from 9% in
WGBS to 34%—and transcription start site (TSS)
states, where the fraction was increased from 2 to 20%.
Overall, less than 4% of correlations involved CpGs in
heterochromatin or repressed states for both MCC-Seq
and WGBS, making these types of regions particularly
difficult to characterize.
(See figure on previous page.)
Fig. 3 The proportion and number of sites of cell type-specific methylation in adipose tissue, naïve T cells (nTC), and whole blood (WB). The red
segments at the top show the proportion of CpGs that are specific to the specific tissue, and the purple segments at the bottom show the proportion of
CpGs that were found in all three cell types. The yellow, green and blue bars show CpGs that are shared between the specific cell type and adipose
tissue, naïve T cells, and whole blood, respectively. Shown is the breakdown in the three cell types for a significant mQTL CpGs (q < 0.1), b significant
ASM CpGs (q < 0.1), c putative epigenetic (filtered for ASM and mQTL q > 0.1) GIT CpGs (GIT q < 0.01). d Enrichment GWAS SNPs associated with
significant ASM in three different tissues—naïve T cells (TC, blue), whole blood (WB, green) and visceral adipose tissue (VAT, red). We show enrichment
for disease-associated loci from eight different traits (celiac disease, Crohn’s disease (CD), inflammatory bowel disease (IBD), ulcerative colitis (UC),
multiple sclerosis (MS), rheumatoid arthritis (RA), type 1 diabetes (T1D), and type 2 diabetes (T2D)) and SNPs associated with ASM
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Next, we examined the enrichment of significant AS
and NAS methylation (|R| > 0.4, p < 0.05) in each of
these genomic features (Fig. 5c–f ). The non-allelic ana-
lysis clearly shows enrichment of the significant negative
correlations (R < -0.4, p < 0.05) in the TSS state and en-
hancers (Fig. 5c–d) confirming our earlier findings [7].
Positive correlations (R > 0.4, p < 0.05) were enriched in
the repressed state. Similarly, when we look at significant
allelic correlations (|R| > 0.4, p < 0.05) at CpGs where we
have ASM (p < 0.05), we replicate the enrichment of
negative correlations in TSS states and the positive cor-
relations in repressed states (Fig. 5e, f ).
In an attempt to disentangle the genetic effects under-
lying functional methylation variation (i.e., correlated
with gene expression), we contrasted functional epigen-
etic methylation and functional genetic methylation. Of
the 3066 AS CpG–gene correlations (n = 414,954 tested),
where AS methylation was strongly correlated to AS
A B
C D
E F
Fig. 4 Density of allelic and non-allelic methylation versus gene expression correlation (R) and cumulative distribution of the absolute allelic and
non-allelic correlation (|R|) for each dataset. a Density plot of significant (p < 0.05) correlations detected among sites (NCpG = 241,687, Ntests =
441,931) tested for allelic and non-allelic correlation for CpGs measured via MCC-Seq. b Density plot of significant correlations for sites (NCpG = 40,315,
Ntests = 58,106) with methylation estimated by WGBS. c Empirical cumulative density function (ECDF) plot of the absolute correlation for sites evaluated
using MCC-Seq. d ECDF for sites evaluated by WGBS. e Smoothed color density scatter plot of sites comparing significant non-allelic (x-axis) and allelic
(y-axis) correlation (p < 0.05 for both correlation tests) for MCC-Seq. Red indicates high density, blue indicates low density, and white indicates no data.
f Smoothed color density scatter plot of significant non-allelic versus allelic correlations for WGBS
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gene expression (|R| > 0.4, p < 0.05), we observed that
65.7% are under genetic control (43.7% with significant
ASM and a further 22% with significant mQTLs) and
25.8% link to putative epigenetic regulation (significant GIT
but no significant ASM or mQTLs). The putatively
epigenetic AS CpGs are strongly enriched (5.7-fold
enrichment, p < 2.2 × 10−16) in repressed regions and in
transcribed regions (2.3-fold, p = 3.2 × 10−8) when com-
pared to the genetically regulated CpGs, which are enriched
near the TSS (3.1-fold, p = 2.97 × 10−16) and enhancers
(1.5-fold, p= 2.53 × 10−14) (Fig. 2c). In fact, 65.7% of corre-
lations have an identified strong genetic methylation basis
(in ASM or mQTLs), while a further 25.8% have imbal-
anced allelic methylation with no identified genetic basis.
A
B
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Fig. 5 a Fold change difference in fraction of CpG regions (three or more consecutive significantly allelically differentially methylated CpGs) in
ChromHMM-assigned state versus the fraction of single significantly allelically differentially methylated CpGs in the same ChromHMM state. The
x-axis lists the eight ChromHMM states and each colored bar shows a different cell type/methylation interrogation technology. b Proportion of
correlations tested in each ChromHMM state with CpG methylation sequenced by WGBS and MCC-Seq. c Fold-enrichment of positively correlated
CpGs evaluated by MCC-Seq in each ChromHMM state. d Fold-enrichment of positive WGBS correlations. e Fold-enrichment of negatively correlated
MCC-Seq CpGs per state. f Fold-enrichment of negatively correlated WGBS CpGs per state
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Linking allelic histone deposition, DNA methylation, and
gene expression
Next we examined the effect of functional CpG methyla-
tion on histone marks, combining ASM and ASE with
chromatin modification data from ChIP-Seq using an
allele-specific histone (ASH) test to measure the allelic
chromatin modification overlapping functional CpGs
with allelic methylation (Fig. 1d, “Methods”).
When comparing genetic to putatively epigenetic
allelic methylation, we observe that genetic allelic
methylation (mQTL or ASM q < 0.1) is much more
strongly linked to a concordant difference in histone
mark deposition as measured by the ASH test using
ChIP-Seq data. We note that the higher methylation al-
lele at genetically regulated CpGs shows a lower rate of
H3K4me1 and H3K27ac deposition (p < 2.2 × 10−16;
Fig. 2d), whereas a substantially smaller difference in
methylation is observed at the putative epigenetically
regulated sites (GIT q < 0.01, mQTL and ASM q > 0.1).
We also found that the largest proportion of significant
interactions occurred when the high chromatin modifica-
tion rate via H3K27ac, H3K4me1, and H3K4me3 tracked
with high gene expression and were found on the low
methylation allele (Fig. 6a). This is consistent with the
roles of these chromatin modifications as activating and
enhancer marks and the methylation indicating repression
of transcription. Conversely, we observed for the more re-
pressive H3K27me3, H3K36me3, and H3K9me3 marks
that the high histone occupancy chromosome was the
same as the high methylation chromosome and was the
allele having lower gene expression. We again observed a
strong effect for the activating and enhancer marks in the
WGBS data, while the more repressive marks did not
show a strong, consistent pattern. Using the MCC-Seq
data we then compared the distribution amongst the dif-
ferent combinations of direction of effect, considering all
levels of differential methylation, expression, and histone,
and the cases where the differential effects were significant
(p < 0.05) for methylation, expression, and histone simul-
taneously (Fig. 6b–e). Here we found that while we tested
roughly the same proportion of allelic sites for all four
possible allelic combinations, the enrichment for the
canonical direction of effect is particularly strong. For
activating H3K27ac (Fig. 6b) and H3K4me1 (Fig. 6c), we
observed high methylation and low histone mark corre-
sponding to low expression as the strongest signal. For re-
pressive H3K36me3 (Fig. 6d) and H3K27me3 (Fig. 6e), we
see high methylation and high histone corresponding to
low expression as the strongest signal instead. We also
used the genotype-independent signal correlation and im-
balance (G-SCI) ASH test, and found that SNPs linked to
ASH are enriched for association to allelic differential
methylation, further strengthening the links between these
allelic effects (Fig. 6f).
Positional allelic methylation in enhancer regions
Finally, we focused on the enhancer signals in ChromHMM
states—specifically, regions where we detect correlation
between gene expression and H3K27ac or H3K4me1
peaks. We note that CpGs have overall high mean methy-
lation (>75%) in transcription and silent states, low mean
methylation (<25%) in the TSS state, and intermediate
methylation in genic enhancer and enhancer states (Fig. 7a;
Additional file 7). We also observed high methylation for
the Polycomb repressed state, detected only in H3K4me1,
and low methylation in the repressed state, only seen in
H3K27ac, highlighting the different locations of these
chromatin modifications. When we look at the methyla-
tion on the allele with high gene expression versus methy-
lation on the low gene expression allele, we see a strong,
consistent negative relationship between gene expression
and methylation for genic enhancer, enhancer, and espe-
cially TSS states, which is consistent with the role of
methylation marking the regulation of gene expression.
We note that many of the CpGs are located near the
enhancer state for both H3K27ac and H3K4me1 (Fig. 7b),
and both marks show most of the CpGs involved at
around 300–500 bp from the center of the ChromHMM
state bin. In the case of H3K27ac, there is also signifi-
cant presence in the TSS state, concentrated in the first
300 bp from the center of the ChromHMM state bin.
The CpGs in the genic enhancer state also showed a
concentration slightly away from the center of the bin
(100–400 bp) as well as further away from the center
(800–900 bp). The majority of the H3K4me1 CpGs fall
in the enhancer state, with some additional sites in genic
enhancer and TSS states. Interestingly, we see the major-
ity of the TSS state CpGs falling 400–500 bp away from
the center, rather than near the center of the bin as with
H3K27ac, indicating that regulatory element “edges”
may be most informative to monitor for function.
Finally, the genic enhancer CpGs are concentrated
slightly away from the center of the bin (100–400 bp) as
in H3K27ac, but without a second concentration further
away from the center. These results show that not only
can aggregated analyses detect enrichment of CpGs near
functional genomic elements by combining with chro-
matin modification data, but that we can see distinctive,
function-dependant positional patterns.
When looking at the positional effect of the GIT
methylation (Fig. 7c), we see for H3K4me1 an overall
negative ratio between the high and low expression
allele, except for a loss of allelic methylation located
600–900 bp away from the genic enhancer state centers
and 200–400 bp from the enhancer center. For H3K27ac,
we again see the canonical negative methylation ratio
between high and low gene expression alleles, except very
distinctly at 500–700 bp from the center of the TSS states
where we see a very strong spike in positive ratios.
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Discussion
We report a comprehensive integrative analysis from
multiple large-scale human epigenomic datasets, across
methylation, transcription, and chromatin modifications.
For the first time we used tests that integrate allelic
events across populations linked either to the reference
allele or purely to recurrent imbalanced methylation
states of chromosomes observable only in population
NGS data. We have not only generated the largest
catalogue of methylation changes in haploid human ge-
nomes, but by combining these three levels of genomic
data with allelic profiling, we reveal novel relationships
A
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D E
Fig. 6 a Proportion of sites showing differential allelic methylation, histone occupancy, and gene expression. All four combinations of high and
low methylation rate, histone occupancy rate, and gene expression are compared, described from the perspective of the high methylation allele,
and whether this allele is the one with high or low histone occupancy, and high or low gene expression (note that high methylation allele with
low histone occupancy also refers to the low methylation allele with high histone occupancy). For the histone marks b H3K27ac, c H3K4me1,
d H3K36me3, and e H3K27me3, we show the proportions of all the differential allelic methylation, histone occupancy, and gene expression
tested (blue), and proportions of the tested sites that passed significance p < 0.05 (red). f The percentage of allelic differentially modified histone
sites as identified by GSCI that have an ASM ratio at the SNP-associated CpG in the top 1% versus the percentage of histone sites not having an
allelic effect detected by GSCI but having an ASM ratio at the SNP-associated CpG in the top 1%
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Fig. 7 (See legend on next page.)
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between genetic and non-genetic allelic variation. Non-
genetic effects are seen in imprinted regions of the
human genome but are also strikingly enriched in classes
of developmental transcription factors. The non-genetic
variation appears to have less involvement in active
allelic chromatin states (28% of functional AS CpG–gene
correlations). Our CpG allelic variation catalogue can be
utilized to intersect with other population variation data-
sets to interrogate potential epigenetically variable (e.g.,
partial imprinting) regions in the genome. However, our
allelic methylation observations are based on terminally
differentiated cells and tissues, whereas these effects may
be rooted in epigenetic memory of allelic exclusion
events not active in the studied cells. The ~350,000
allelic events not driven by detectable genetic or known
imprinted events call for further studies in developmen-
tal cell lineages to further clarify their potential func-
tional roles.
We show that allelic CpG methylation and gene ex-
pression analysis allows for more sensitive detection of
functional epigenetic effects and has the ability to reveal
correlations not seen in non-allelic methylation to gene
expression analyses. As each allele can contribute a sep-
arate methylation/expression data pair, allelic analysis
has the advantage of potentially doubling the number of
data points usable for the correlation analysis. As well, it
is particularly interesting for disentangling relationships
at hemi-methylated sites, where intermediate levels of
gene expression and methylation may confound non-
allelic methylation and expression analysis, but resolving
the alleles separately shows different methylation rates
and gene expression rates. While non-allelic analysis of
MCC-seq data still results in more significant correlated
sites than non-allelic analysis, most of the additional
non-allelic correlations are far weaker—the bulk of the
non-allelic correlations have |R| < 0.4, whereas over half
the allelic correlations have |R| > 0.4. This trend is repli-
cated when we look in the WGBS dataset, where there
are distinctly far fewer significantly correlated sites and
the correlations are higher when passing significance
due to the smaller numbers of samples involved.
However, allelic analysis comes at the price of a
reduced read depth for the individual alleles, thereby
increasing the error rates in the allelic methylation and
expression rate estimation. We observe that the allelic
analysis of the lower coverage WGBS data shows fewer
significant highly correlated sites, highlighting the
impact of lower read depth coverage when profiling all
CpGs genome-wide. Conversely, when examining the
MCC-Seq data—where the read coverage is focused on a
much smaller subset of the genome and we have a larger
number of samples—we are able to identify a far greater
number of significant, highly correlated sites. Developing
deeper and larger WGBS datasets will be useful to
further investigate some of our observations, such as
primary concentration of epigenetic variation outside
canonical regulatory elements. Further meta-analyses,
incorporating additional eQTL/ASE, mQTL/ASM and
hQTL/AS-ChIP sequencing datasets, would allow us to
independently confirm the same relationships in similar
cells, determine whether the observed relationships are
maintained in more distantly related cell types, as well
as further differentiate cell type-specific patterns. Corre-
sponding sequencing datasets in other species would
allow us to investigate the evolutionary conservation of
these multi-level effects.
The large number of relationships detected uniquely
by allelic or non-allelic analysis alone indicates that these
analyses can identify fundamentally different relation-
ships between the epigenome and the transcriptome.
Non-allelic correlation between methylation and gene
expression focuses on global trends of methylation ex-
pression between cells affecting global gene expression
levels. Allelic correlation, however, normalizes the gene
expression across both alleles in a cell, and so the trend
is no longer across the total gene expression between
cells, but rather a normalized allelic imbalance of ex-
pression, as affected by allelic methylation. We see that
while allelic functional methylation analysis is highly
sensitive and reveals many non-canonical relationships
outside regulatory elements. On the other hand, the sub-
set of variation in enhancers/promoters coinciding with
allelic active histone deposition results in a very coherent
picture that shows the expected relationships between the
epigenetic layers of control and functional gene expres-
sion. These strong, consistent patterns indicate that com-
bined allelic analysis of multiple epigenetic layers allows
us to track interactions with direct functional effects.
We also see the canonical relationship between methy-
lation and gene expression in an allelic manner, with the
high gene expression allele being coincident with the
low methylation allele. However, we see a positional loss
of this canonical relationship (in H3K4me1) or even re-
versed to a positive relationship (in H3K27ac), a short
(See figure on previous page.)
Fig. 7 a The distribution of the mean methylation of CpGs by ChromHMM state, for CpGs in ChromHMM states where we see high correlation
between gene expression and H3K27ac (left) or H3K4me1 (right) histone peaks. Bar graphs show the log2 mean allelic ratio of the methylation on
the high gene expression allele versus the low gene expression allele (green; indicating p < 0.05) b Positional distribution of CpGs by distance
from the center of the ChromHMM state, for all the ChromHMM states having at least 100 CpGs c Summary of log2 mean allelic methylation
ratio of CpGs at each distance from the center of the ChromHMM state bin, for the high gene expression allele versus low gene expression allele
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distance from the center of the enhancer feature (Fig. 7c).
The loss of allelic methylation may delineate the bound-
ary of the enhancer region and the adjacent “marginal”
CpGs can actually serve as sensors of enhancer element
function, showing strongest correlation with expression
states. Interestingly, it appears that the promoters of
genes with expression coupled to H3K27ac deposition
have distinctly different positional methylation architec-
ture, with a larger density of CpGs clustered by the cen-
ter of the TSS region, whereas for H3K4me1 the CpGs
are grouped (Fig. 7b).
Conclusions
We combine allelic analysis across multiple epigenomic
and transcriptomic layers, revealing interactions between
the varied layers of the effects. Models that can simul-
taneously use the allelic and non-allelic data could allow
us to supplement the non-allelic analysis with allelic in-
formation when it is available, rather than analyzing this
information in a completely disjoint manner, and with-
out losing the relationships that allelic or non-allelic
analyses alone can discover. As it has been shown that
correlations link many layers of functional signals in an
allele-specific manner in more limited contexts (e.g.,
GM12878 cells [35]), further analyses could go beyond
coordinating three layers of effects and consider multiple
histone marks and transcription factor binding simultan-
eously with gene expression and methylation in an allelic
manner in a population context.
At present, we are using non-allelically resolved his-
tone mark datasets to train the ChromHMM model, and
we show different behavior of the epigenome and tran-
scriptome in different states. We could more tightly
integrate allelic data into the genomic state analysis by
adapting the allelic information and incorporate allele-
specific epigenomic information in the ChromHMM
inputs so that the states themselves take into account
allelic information, while integrating across multiple
epigenome and transcriptome layers, and see how this af-
fects the model of the genome that is generated. As well,
our case study demonstrates how the allelic relationships
between methylation and histone marks are altered in the
different forms of the disease, further emphasizing the fu-
ture utility of allelic resolution in disentangling the func-
tional outcome. Finally, more sequencing in distinct
tissues and cell types would allow us to confirm the pre-
liminary cell-specific methylation results we observe as
well as allow us to investigate the interaction of cell-
specific effects across the epigenetic layers.
In summary, we have generated the largest combined
human allele-specific methylation, chromatin modifica-
tion, and transcription dataset to date (Additional files 2,
3, 4, 6, and 7). We show allelic methylation enables dis-
covery of novel links to transcription, whereas total
methylation shows weaker correlations in layers of the
epigenome. We further demonstrate that harnessing the
power provided by allelic resolution across methylation,
transcription, and chromatin modification is key to
interpreting population variation in our epigenomes and
its alterations in disease.
Methods
Sample collections
We recruited 208 donors from the Cambridge NIHR
BioResource as a representative sample of healthy indi-
viduals from the general UK population. Whole blood
was used to purify “classic” naive CD4+ T cells (CD4 +
CD45RA+, average purity 93%) using a multi-step purifi-
cation strategy. Purified cell aliquots were pre-processed,
stored, and transported to processing institutes for
sequencing as previously described [34].
We obtained 114 visceral adipose tissue (VAT)
samples from the Quebec Heart and Lung Institute’s
(Quebec City, Quebec, Canada) Quebec Tissue Bank
collection of 1906 severely obese men (N = 597) and
women (N = 1309) that underwent biliopancreatic diver-
sion with duodenal switch [36] between June 2000 and
July 2012. The VAT samples were obtained as previously
described [37] and processed for methylation sequencing
as reported in Allum et al. [21] and below.
We obtained 599 whole blood samples from 358
individuals in the framework of the EGEA (https://egeanet.
vjf.inserm.fr/), a French longitudinal cohort study based on
an initial group of asthma cases and their first-degree
relatives and controls (first survey EGEA1). The protocol
and descriptive characteristics have been described
previously [38–42].
Blood samples from the Uppsala Bioresource, Uppsala,
Sweden were drawn from 28 normal healthy Swedish in-
dividuals and purified to extract T cells (CD14− CD4+)
and monocytes (CD14+). Nine skeletal muscle human
samples were also obtained. Sequencing data are avail-
able through the McGill Epigenomics Mapping Portal
(http://epigenomesportal.ca).
These samples and the sequencing datasets derived
from them are described globally in Fig. 1, with further
detail specifying the cell types and mean read depth
available for each dataset in Additional file 5: Figure S2
and Additional file 8: Table S1. At each step, we per-
formed tests on each dataset (all samples of a particular
cell type and methylation sequencing methodology
combination, matched with RNA-Seq and ChIP-Seq if
needed) and report the combined results of these tests.
Methylation sequencing
Targeted bisulfite sequencing (MCC-Seq) and whole
genome bisulfite sequencing was performed as previ-
ously described [21]. A whole-genome sequencing
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library is prepared and bisulfite converted, amplified and
a capture enriching for targeted bisulfite-converted DNA
fragments is carried out. The captured DNA is further
amplified and sequenced. More specifically, whole-
genome sequencing libraries were generated from 700 to
1000 ng of genomic DNA spiked with 0.1% (w/w)
unmethylated λ DNA (Promega) previously fragmented
to 300–400 bp peak sizes using the Covaris focused-
ultrasonicator E210. Fragment size was controlled on a
Bioanalyzer DNA 1000 Chip (Agilent) and the KAPA
High Throughput Library Preparation Kit (KAPA
Biosystems) was applied. End repair of the generated
dsDNA with 3′ or 5′ overhangs, adenylation of 3′ ends,
adaptor ligation, and clean-up steps were carried out as
per KAPA Biosystems’ recommendations. The cleaned-
up ligation product was then analyzed on a Bioanalyzer
High Sensitivity DNA Chip (Agilent) and quantified by
PicoGreen (Life Technologies). Samples were then bisul-
fite converted using the Epitect Fast DNA Bisulfite Kit
(Qiagen) according to the manufacturer’s protocol.
Bisulfite-converted DNA was quantified using OliGreen
(Life Technologies) and, based on quantity, amplified by
9–12 cycles of PCR using the Kapa Hifi Uracil + DNA
polymerase (KAPA Biosystems) according to the manu-
facturer’s protocol. The amplified libraries were purified
using Ampure Beads, validated on Bioanalyzer High
Sensitivity DNA Chips, and quantified by PicoGreen.
For targeted bisulfite sequencing, we used the MCC-Seq
protocol developed and optimized in collaboration with
Roche NimbleGen R&D. SeqCap Epi Enrichment System
protocol (Roche NimbleGen) was carried out for the
capture. The hybridization procedure of the amplified
bisulfite-converted library was performed as described by
the manufacturer using 1 μg of total input of library,
which was evenly divided by the libraries to be multi-
plexed, and incubated at 47 °C for 72 h. Washing and
recovering of the captured library, as well as PCR amplifi-
cation and final purification, were carried out as recom-
mended by the manufacturer. The quality, concentration,
and size distribution of the captured library were deter-
mined by Bioanalyzer High Sensitivity DNA Chips.
Sequencing of both the MCC-Seq libraries and the
WGBS libraries was performed on the Illumina HiSeq2000/
2500 system using 100-bp paired-end sequencing.
WGBS and MCC-Seq data processing
In-house generated methylome libraries were aligned
using BWA 0.6.1 [43] after converting all the reads in
bisulfite mode to the human hg19/GRCh37 genome
reference. Both reads in a pair were trimmed of any
low-quality sequence at their 3′ ends (with Phred
scale score ≥30). Post-process read mappings were made
as previously described [44], including clipping 3′ ends of
overlapping read pairs in both forward and reverse strand
mappings, filtering duplicate, low-mapping quality reads,
read pairs not mapped at the expected distance based on
the library insert size, as well as reads with more than 2%
mismatches. Methylation calls of individual CpGs were
extracted using Samtools in mpileup mode. CpGs overlap-
ping SNPs from dbSNPs (137) and CpGs located within
ENCODE DAC blacklisted regions or Duke excluded re-
gions [35] were discarded. CpGs with the number of total
reads less than 5× were also discarded.
Genotyping and phased genome
The T-cell, mono cell (in Temporal Change project), and
muscle tissue samples were genotyped using the Illumina
HumanOmni2.5-8 (Omni2.5 M) or HumanOmni5-4
(Omni5M) BeadChip according to protocols recom-
mended by Illumina. Genotypes of BluePrint samples were
obtained from whole genome sequencing [34]. Genotypes
of samples from other tissues which were not genotyped
using BeadChip were inferred directly from the WGBS
data using BisSNP [45]. Rare variants and singletons were
confirmed using targeted sequencing data of coding and
non-coding regulatory regions.
We used 1000 Genomes project data as a reference set
(release 1000G Phase I v3, updated 26 Aug 2012) for the
imputation of genotypes (either genotyped from Illumina
BeadChip or inferred from BisSNP). Untyped/un-inferred
markers were inferred using algorithms implemented in
IMPUTE2 [46].
mQTLs were computed using matrixQTL using
default parameters, considering only cis-effects within
250 kb and minor allele frequency of 0.05. P values were
corrected by false discovery rate (FDR) [47].
RNA-Seq
RNA-Seq was performed as described previously. RNA
was isolated using the miRNeasy Mini Kit (Qiagen)
according to the manufacturer’s protocol. We used as
input 500 ng RNA (RNA integrity number >7) for library
preparations using the Illumina TruSeq Stranded Total
RNA Sample preparation kit according to the manufac-
turer’s protocol. Final libraries were quality controlled
on a Bioanalyzer and underwent 100-bp paired-end se-
quencing on the Illumina HiSeq2000 system. Generated
raw reads were filtered for quality (phred33 ≥ 30) and
length (n ≥32), and adapter sequences were removed
using Trimmomatic v.0.32 [48]. Reads passing filters
were then aligned to the human reference (hg19) using
TopHat v.2.0.10 [49] and bowtie v.2.1.0 [50]. UCSC gene
counts for non-allelic analysis were obtained using
htseq-count v.0.6.1 [51].
ChIP-Seq
Sonication of nuclei was performed on a BioRuptor
UCD-300 for 90 cycles, 10 s on, 20 s off, centrifuged
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every 15 cycles, chilled in a 4 °C water cooler. Samples
were checked for sonication efficiency using the criteria of
150–500-bp by gel electrophoresis. The ChIP reaction was
performed on a Diagenode SX-8G IP-Star Compact using
Diagenode automated Ideal Kit reagents (C01010011).
Protein A beads (25 μL) were washed and then incubated
with 3–6 μg of antibody and two to four million cells of
sonicated cell lysate combined with protease inhibitors for
10 h, followed by a 20-minute wash cycle with provided
wash buffers. Reverse cross-linking took place on a heat
block at 65 °C for 4 h. ChIP samples were then treated
with 2 μl RNAse cocktail at 65 °C for 30 minutes followed
by 2 μL Proteinase K at 65 °C for 30 minutes. Samples
were then purified with a Qiagen MiniElute PCR purifica-
tion kit as per the manufacturers’ protocol. Library prepar-
ation was carried out using Kapa HTP Illumina library
preparation reagents. Briefly, 25 μl of ChIP sample was in-
cubated with 20 μl end repair mix at 20 °C for 30 minutes
followed by Ampure XP bead purification. A tailing, bead-
bound sample was incubated with 50 μL buffer enzyme
mix at 30 °C for 30 minutes, followed by PEG/NaCl purifi-
cation. Adapter ligation, further Ampure purification, and
library preparation were completed by 14 cycles of PCR
amplification. Size selection was performed using a Sage
Pippin prep system and set to collect 200–400-bp
fragments, targeting a 300-bp peak fragment size and final
libraries were purified with Qiagen GeneRead Size
Selection kit.
ChIP libraries were sequenced at McGill using Illu-
mina HiSeq 2000 with 100-bp single-ended reads. Gen-
erated raw reads were filtered for quality (phred33 ≥ 30)
and length (n ≥ 32), and adapter sequences were re-
moved using Trimmomatic v.0.22 [52]. Reads passing fil-
ters were then aligned to the human reference (hg19)
using BWA v.0.6.1. Peak calls were obtained using
MACS2 v.2.0.10.07132012 [4].
Allele-specific methylation pipelines
Imputed and phased genotypes were used to create two
allele-specific copies of the reference genome. Reads
were then mapped to these two reference genomes using
the sample pipeline as described above [44], except that
no mismatches were allowed during the alignment step
in order to ensure that reads coming from a specific al-
lele will map to the appropriate reference. An in-house
software takes the genotypes and their positions and
scans the alignment files to obtain the methylation states
of the CpGs surrounding the alleles. The width of the
area scanned spans 500 bp upstream and downstream of
a heterozygous SNP. For the cases where imputed
phased genomes are not available, we considered the
methylation status of CpGs from paired-end reads
containing the same heterozygous SNP (as inferred by
BisSNP). As a strand-specific WGBS protocol, reads
mapped from both strands were counted. When there is
a “C/T” heterozygous SNP neighboring a CpG, only
reads from the reverse strand were considered while for
a “G/A” heterozygous SNP, only reads from the forward
strand were considered. In order to appropriately esti-
mate methylation levels, a bare minimum number of five
reads per allele (from both strands) is required. We then
summed the reads across all individuals based on alleles’
genotyping to detected genetic ASM. After obtaining the
methylation states of individual CpGs per allele, the
differential methylation between the two alleles at CpGs
were then determined using a two-sided Fisher’s exact
test. CpGs with p < 0.05 were considered nominally
significant.
For each cell type, we performed a test of methylation
imbalance (GIT) by merging allele-specific methylation
reads across samples. At a CpG, we categorized one
allele per sample as the high methylation allele and the
other as the low methylation allele. We then considered
the total methylated and total unmethylated reads for
the high methylation alleles, and similarly for the low
methylation alleles. In this way, we obtained sample-
merged read counts of individual CpGs per allele. Differ-
ential methylation between high and low methylation
alleles at CpGs was then determined using a two-sided
Fisher’s exact test. CpGs showing p < 0.05 were consid-
ered nominally significant.
To determine significant ASM and mQTL sites, we
applied FDR [47] at q < 0.1. For GIT, we performed a one-
sided Fisher’s exact test, corrected by the total probability
of all possible contingency tables where methylation on
the high methylation allele is greater than the low methy-
lation allele. We then applied a more stringent FDR cutoff
of q < 0.01 to identify the significant GIT sites. Putative
epigenetically regulated CpGs are significant imbalanced
CpGs (corrected q < 0.01) having no significant genetic
methylation (ASM and mQTL q ≥ 0.1).
Allele-specific chromatin modifications
Reads from ChIP-seq data were trimmed for quality
(phred33 ≥ 30) and length (n ≥ 32) using Trimmomatic
v.0.22 [52]. The filtered reads were aligned to the hg19
reference genome using BWA v.0.61. We then binned
genomic regions with 100 bp-window to get the aligned
read counts and arbitrarily chose top 300 K of 100-bp
bins as the candidate peaks for different types of histone
markers, including H3K27ac, H3K27me3, H3K36me3,
H3K4me1, H3K4me3, and H3K9me3. When calculating
the allele-specific marker regions, for each heterozygous
SNP within the region we counted the number of reads
of different origin that overlapped with the SNPs. The
allele bias was then tested using a binomial test against
the null hypothesis that the ratio between these two
alleles is equal. SNPs with p < 0.05 were considered
Cheung et al. Genome Biology  (2017) 18:50 Page 17 of 21
allele-specific. The allelic ratio for the high methylation
allele was computed as 0.5-fraction of ChIPSeq reads on
the high methylation allele compared to the total (high
and low allele) reads, and similarly for the low methyla-
tion allele using the fraction of ChIPSeq reads on the
low methylation allele.
Gene expression versus RNA expression correlations
Non-allelic methylation was measured as the percentage
of methylated CpG reads compared to the total methyl-
ated and unmethylated reads overlapping the CpG site.
Allelic methylation considers only reads with a heterozy-
gous SNP that could be resolved to one of the two
chromosomes:
MethylationalleleA ¼ unmethylatedReadsalleleAunmethylatedReadsalleleA þmethylatedReadsalleleA
Non-allelic gene expression was measured as the
library size and quantile normalized, asinh transformed
read counts of aligned RNA reads:
NonAllelicExpression ¼ asinh quantileNormalised GeneReads
TotalReads
  
Allelic gene expression only considered reads resolved
to one of the two chromosomes. Gene expression for an
allele A was the number of reads aligning to allele A
divided by the total of reads aligning to allele A and
reads aligning to allele B.
AllelicExpressionalleleA ¼ readsalleleAreadsalleleA þ readsalleleB
Pearson correlation was used to evaluate relationships
between CpGs and genes with TSS within 50 kb of the
CpGs, for cases where at least three samples had match-
ing gene expression and methylation data.
ChromHMM genomic states
An eight-state ChromHMM [25] model trained using
default parameters on a panel of 352 T-cell, monocyte,
and muscle histone (H3K27ac, H3K27me3, H3K36me3,
H3K4me1, H3K4me3, and H3K9me3) ChIP-Seq datasets
was used to assign states to each CpG position. State
identities were assigned based on the ChromHMM
report (Additional file 9).
G-SCI test
We also performed allelic regulatory QTL analysis on
multiple histone marks using a recent published method
called the genotype-independent signal correlation and
imbalance (G-SCI) test [53]. It was originally designed
for detecting histone acetylation QTLs (haQTLs) from
deep, long-read ChIP-seq data without requiring geno-
typing or whole genome sequencing. It first called vari-
ants with base calling information directly from the
ChIP-seq sequence reads in peaks and then correlated
these variants with chromatin states to prioritize the
genetic variants. The G-SCI test itself only required vari-
ant base calling information and the peak height score
information; thus, it can also apply to detect the associ-
ation between any histone marker peak regions and
concerned variants within peak regions. We applied the
G-SCI test to all available histone mark ChIP-Seq data
with SNPs detected from imputed genotypes of each
corresponding individual. Peak heights of each region
were normalized by quantile-quantile normalization and
were finally log-transformed. We also filtered out SNPs
if the total number of non-reference reads across all
ChIP-Seq data was less than five or none of the ChIP-
seq datasets had three or more non-reference reads.
After obtaining the p value of each G-SCI test, the
Benjamini and Hochberg (BH) approach for FDR [54]
was used to correct for multiple testing and the adjusted
p value of 0.01 was chosen as the significant cutoff.
ASM versus ASH
We mapped heterozygous SNP-based histone marker
read counts from two alleles to CpGs by matching with
the same SNPs. For GIT, when the imputed phased gen-
ome was available, then ASH counts of SNPs 500 bp
away from the corresponding CpGs were added up.
Otherwise, when an imputed phased genome was not
available and for ASM, only the ASH counts of the same
SNPs were considered.
Genome feature association
Based on human genome hg19, annotation tables of
genomic features were downloaded from the UCSC
Genome Browser [55] on 10 September 2013. Overlap-
ping between any two regions were calculated using
bedtools [56].
Positional allelic methylation in enhancer regions
Focusing on the deposition of the enhancer histone marks
H3K27ac and H3K4me1, we linked to allelic gene expres-
sion, histone deposition, and methylation back to the gen-
omic states and looked at the positional pattern of allelic
methylation. We identified ChromHMM state regions
where we observed a correlation (|R| > 0.4, p < 0.05) be-
tween gene expression and the histone mark deposition in
nTC cells (100-bp windows from the center of H3K27ac
peaks, 500-bp windows for H3K4me1 peaks) overlapping
the state region, considering ChromHMM state regions
up to 10 kb in size. For each of these putative enhancer re-
gions, we then phased the allelic methylation for all CpGs
in the region based on the high gene expression and the
low gene expression allele—for genes with multiple tran-
scripts, we selected the transcript isoform with the highest
number of exonic reads, breaking ties with the largest
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overall gene reads. CpGs were grouped based on their ab-
solute distance from the center of the bin in 100-bp incre-
ments, calculating overall methylation on each allele for
each bin separately.
Disease GWAS enrichment of ASM event
We used GWAS variants from eight diseases (celiac dis-
ease [27], Crohn’s disease [28], inflammatory bowel dis-
ease [28], ulcerative colitis [28], multiple sclerosis [29],
rheumatoid arthritis [30], type 1 diabetes [31], and type 2
diabetes [32]) for which we retrieved publicly available
genome-wide summary statistics [34]. We tested genome-
wide enrichment for independent variants (LD r2 < 0.1)
nominally associated with disease (p value ≤10−5) among
significant ASM-SNPs (q < 0.1) or with a SNP in high LD
(r2 > 0.8). The background was defined as all independent
GWAS SNPs tested overlapping any SNPs’ ASM that was
tested. The significance of the enrichment was assessed
using Fisher’s exact test. LD information was calculated
for each SNP ±250 kb using phased data from whole gen-
ome sequencing of the whole blood samples.
Additional files
Additional file 1: Description of MCC-Seq capture panel. This file
contains: (1) summary of CpGs and genomic regions targeted by the
MCC-Seq capture panel design (.xlsx Excel spreadsheet format), and (2) a
list of the targeted regions (.bed text file). (ZIP 3465 kb)
Additional file 2: Summary of AS and NAS methylation tests on the
2.2 million CpGs tested across any of the datasets. This file contains a
file of tab-separated values (.txt text file) with the following columns:
(1) CpG chromosome, (2) CpG location, (3) corrected GIT p value,
(4) corrected mQTL p value, (5) corrected ASM p value, (6) ChromHMM
state. (ZIP 19804 kb)
Additional file 3: High-confidence non-genetic CpG regions. This file
contains a list of genomic regions (.bed text file) containing at least 15
consecutive CpGs and where all CpGs did not show significant genetic
methylation (ASM and mQTL q ≥ 0.1) but showed significant imbalanced
allelic methylation (GIT q < 1 × 10−5), and where the median imbalanced
allelic methylation was highly significant (loge(q) < −10). (ZIP 8 kb)
Additional file 4: GREAT analysis results of the high-confidence
non-genetic CpG regions. This file lists over-representation analysis results
from GREAT for GO biological process, Interpro, and HGNC Gene Families.
For the GO biological process analysis, child terms of the GO term
“developmental process” are highlighted in green, and child terms of the
GO term “metabolic process” are highlighted in yellow. For Interpro and
HGNC gene families, homeobox/homeodomain genes are highlighted
in green and cadherin/adhesion genes are highlighted in yellow.
(XLSX 17 kb)
Additional file 5: Figure S1. Validation using 450 k array. Figure S2.
Detailed description of samples per cell type. (PDF 440 kb)
Additional file 6: AS and NAS CpG methylation to RNA expression
correlations. This mini-website describes the file format and links to
individual correlation results for each cell type (.txt tab-separated text file).
(ZIP 18638 kb)
Additional file 7: Allelic methylation in enhancer peaks. In this file, we
report the ChromHMM bin and the allele-sepcific CpG methylation and
RNA read coverage at CpGs within H3K27ac and H3K4me1 ChIP-Seq
peaks. (XLSX 1899 kb)
Additional file 8: Table S1. This file details for each cell type mean fold
coverage (for CpG methylation sequencing) and total aligned reads
(for RNA-Seq and ChIP-Seq). (XLSX 10 kb)
Additional file 9: ChromHMM state report. This file is the report generated
after machine learning of the eight-state ChromHMM model. (PDF 261 kb)
Additional file 10: Source code. This file contains the code for
generating the ASM p values: Get_CpG.SNP.pairs.mergedSamples.
Profile.PhasedAlleles.pl (.pl perl code script), Get_ASMsite_FisherTesting.
PhasedAlleles.MergedReads.r (.R R statistics script); the code for
generating the GIT p values: Get_CpG.SNP.pairs.mergedSamples.
Profile.FlippedHL.pl (.pl perl code script), Get_ASMsite_FisherTesting.
FlippedHL.MergedReads.r (.R R statistics script); and the code for the GIT
q value statistic correction: GIT-qvalue.correction.R (.R R statistics code
script). (ZIP 8 kb)
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